The NMDA antagonist model for schizophrenia: promise and pitfalls
- PMID:9754841
- DOI: 10.1055/s-2007-979354
The NMDA antagonist model for schizophrenia: promise and pitfalls
Abstract
Drug models have been extensively used to study the pathophysiology of schizophrenia. While they provide good insight into the neurobiology of this disorder, they have several shortcomings, which if known, help in the interpretation of results. In this paper we will discuss these shortcomings in general, and in relation to the N-methyl D-aspartate antagonist model for schizophrenia. This model has recently received a great deal of attention since both phencyclidine and the structurally related drug ketamine, produce symptoms that extend beyond psychosis per se to include other symptoms associated with schizophrenia. In fact, subanesthetic doses of ketamine in healthy individuals produce not only paranoia and perceptual alterations but also thought disorder, negative symptoms, cognitive deficits, as well as impairment on a number of electrophysiologic tests known to be abnormal in schizophrenia. These effects of ketamine will be discussed with a particular emphasis on implications for the pathophysiology and therapeutics of this disorder.
Similar articles
- [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.Mechri A, et al.Encephale. 2001 Jan-Feb;27(1):53-9.Encephale. 2001.PMID:11294039Review.French.
- [Receptor antagonist of NMDA and animal models of schizophrenia].Bian SZ, Zhang J, Liu WL, Sun ZH, Gu ZL, Jiang XG.Bian SZ, et al.Fa Yi Xue Za Zhi. 2009 Dec;25(6):443-6.Fa Yi Xue Za Zhi. 2009.PMID:20225623Review.Chinese.
- [Pharmacological modulation of the effects induced by ketamine at subanesthetic doses].Mechri A, Micallef J, Blin O, Saoud M, Daléry J, Gaha L.Mechri A, et al.Therapie. 2001 Sep-Oct;56(5):617-22.Therapie. 2001.PMID:11806303Review.French.
- Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA.Gouzoulis-Mayfrank E, et al.Pharmacopsychiatry. 2005 Nov;38(6):301-11. doi: 10.1055/s-2005-916185.Pharmacopsychiatry. 2005.PMID:16342002Clinical Trial.
- The acute effects of NMDA antagonism: from the rodent to the human brain.Gunduz-Bruce H.Gunduz-Bruce H.Brain Res Rev. 2009 May;60(2):279-86. doi: 10.1016/j.brainresrev.2008.07.006. Epub 2008 Jul 30.Brain Res Rev. 2009.PMID:18703087Review.
Cited by
- Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring.Stephan KE, Friston KJ, Frith CD.Stephan KE, et al.Schizophr Bull. 2009 May;35(3):509-27. doi: 10.1093/schbul/sbn176. Epub 2009 Jan 20.Schizophr Bull. 2009.PMID:19155345Free PMC article.Review.
- Psychosis: atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty?Sharp FR, Hendren RL.Sharp FR, et al.Epilepsy Behav. 2007 Jun;10(4):515-20. doi: 10.1016/j.yebeh.2007.02.014. Epub 2007 Apr 6.Epilepsy Behav. 2007.PMID:17416210Free PMC article.Review.
- Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia.Castner SA, Goldman-Rakic PS, Williams GV.Castner SA, et al.Psychopharmacology (Berl). 2004 Jun;174(1):111-25. doi: 10.1007/s00213-003-1710-9. Epub 2004 Jan 20.Psychopharmacology (Berl). 2004.PMID:15205882Review.
- Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy.Baldinger-Melich P, Spies M, Bozic I, Kasper S, Rujescu D, Frey R.Baldinger-Melich P, et al.Wien Klin Wochenschr. 2025 Mar;137(5-6):134-147. doi: 10.1007/s00508-024-02358-w. Epub 2024 Apr 17.Wien Klin Wochenschr. 2025.PMID:38662240Review.
- A subanesthetic dose of ketamine in the Rhesus monkey reduces the occurrence of anticipatory saccades.Ameqrane I, Wattiez N, Pouget P, Missal M.Ameqrane I, et al.Psychopharmacology (Berl). 2015 Oct;232(19):3563-72. doi: 10.1007/s00213-015-4005-z. Epub 2015 Jul 9.Psychopharmacology (Berl). 2015.PMID:26153067
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical